I filed what has to be the largest complaint in the history of the Florida Department of Health against Drs. Loren and Mark Clayman. Out of 264 combined complaints filed, the DOH staff brought only one complaint against Dr. Loren Clayman to be heard by the Board of Medicine.
The DOH did not recommend revocation or even suspension of Dr. Loren Clayman’s license. Instead, it recommended – and the Board of Medicine approved – a settlement that cited Dr.
I filed my 264 clients’ claims in a single complaint and provided the DOH with more than 10 banker’s boxes full of records, documents, photographs, charts, and a video. It took years to get a response from the DOH.
This is a sad day for women in Florida. If the Board had heard from other victims and seen some of the critical evidence I provided to the DOH, I expect it would have rejected the DOH’s weak deal with Clayman. The Board of Medicine could not do its job properly when it was only shown a tiny fraction of the evidence.
For BIA-ALCL cases, attorney Dena Young Lebovic with Ross Feller Casey and co-counsel have 50+ BIA-ALCL cases filed in the New Jersey Superior Court.
1. Sauder Schelkopf Attorney at Law, Berger Montague, and Mazie Slater Katz & Freeman filed a class action lawsuit against breast implant manufacturer Allergan and its Biocell Textured Breast Implant on August 16, 2019. The case is Jane Doe I, et al. v. Allergan, Inc., et al. .”The women who filed the lawsuit said they wouldn’t have gotten Biocell implants if they knew about the cancer link. Neither of the women have BIA-ALCL”, from Insider.
In the early 2000s, Allergan and Mentor were approved for premarket Investigational Device Exempt (IDE) studies where a limited number of plastic surgeons were allowed to use silicone breast implants, accordingly they were supposed to inform women of the study and follow up on them. In November 2006, Mentor and Allergan silicone breast implants were conditionally approved and six postmarket studies were to be conducted, see Mentor Approval Order and Allergan (formerly Inamed) Approval Order . The manufacturer premarket and postmarket studies have overall failed to follow up on women and provide real statistics on health problems that arise.
The two primary reasons are for the increased risks of cancer and of rupturing. See Case No. 500-06-000966-198. Read more on CTV News and Global News.
Allergan class action on September 20, 2019, see complaint. 4. On October 8, 2019 Megan McBride filed a class action lawsuit against Allergan with Levin Papantonio in the Central District of California.
In July 2019, after months of countries around the world recalling Allergan textured breast implants, the FDA requested Allergan to recall its textured breast implantsfrom the US market. Allergan responded with a global recall of silicone and saline textured breast implants and tissue expanders.